Antibodyomes for faster Discovery of Biologicals, with Memo Therapeutics

August 26, 2016 - 1 minute

After delighting ourselves with fabulous French gastronomy in Nancy, it’s time to say our farewells and head to the next border. Basel is our final destination. Our goal? Get to know a bit more of Swiss-based company Memo Therapeutics, our Biotech of the Week.

City: Basel, Switzerland

Founded: 2010

Employees: 10

Financial Data: €2.1M Total Raised (as of 06/2016)

CEO: Armin W. Mäder

Content continues below

Related Content


Mission: Memo Therapeutics develops complete antibody repertoires (antibodyomes) of humans and animals, in order to have cost and time-effective molecular cloning, biobanking and expression screening.

The result is MemoMAB, a platform that bypasses the major bottlenecks in antibody discovery. It currently keeps expression libraries (coupled with direct expression screening) of human and rabbit antibodies.

memo therapeutics memomab antibody discovery

Comment: Memo Therapeutics started out as spin-off out of the Swiss Federal Institute of Technology (ETH Zurich). After raising a modest Series A in 2015, the Biotech published its first proof-of-concept and recently announced the start of its first client project.

Besides partnering with its platform, Memo Therapeutics is starting with the development of its own pipeline. It is aiming for infectious diseases, cancer, and autoimmune diseases.

Content continues below

Related Content

Feature Image Credit: Labiotech Map


You might also be interested in the following: